Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01466725 · ClinicalTrials.gov registry record · Phase 2
A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus
A Phase 2 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01466725 is a Phase 2 study that was terminated before completion, run by Celgene. The registered enrollment target is 5 participants.
The verdict
NCT01466725, a Phase 2 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of the study is to assess if CC-930 is safe and tolerable in treating subjects with Discoid Lupus Erythematosus. Pharmacokinetic and pharmacodynamics will also be evaluated.
Interventions
- DRUG Placebo
- DRUG CC-930
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-11-01 |
| Est. Completion | 2012-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01466725
The ClinicalTrials.gov registry entry for NCT01466725 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01466725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01466725 about?
NCT01466725 is a clinical study titled "A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus". The purpose of the study is to assess if CC-930 is safe and tolerable in treating subjects with Discoid Lupus Erythematosus. Pharmacokinetic and pharmacodynamics will also be evaluated.
What is the current status of trial NCT01466725?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2011-11-01. Estimated completion is 2012-07-30.
What interventions are being tested in trial NCT01466725?
The interventions under investigation include: Placebo (DRUG), CC-930 (DRUG).
Who is sponsoring clinical trial NCT01466725?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.